Progranulin is a multifunctional growth factor mainly expressed in neurons and microglia. Loss-of-function mutations in the Granulin (GRN) gene are causative of frontotemporal dementia with TAR DNA-binding protein-43 inclusions. We reported the case of a 51-year-old male patient affected by sporadic agrammatic variant of primary progressive aphasia, in whom we identified a novel heterozygous deletion in the exon 6 (g.10338_39delAG, p.Arg161GlyfsX36). Plasma progranulin levels were significantly reduced and in silico analysis predicted a premature termination codon. This case expands our knowledge on GRN mutations in frontotemporal dementia.
CrutsM, GijselinckI, van der ZeeJ, EngelborghsS, WilsH, PiriciD, RademakersR, VandenbergheR, DermautB, MartinJJ, van DuijnC, PeetersK, SciotR, SantensP, De PooterT, MattheijssensM, Van den BroeckM, CuijtI, VennekensK, De DeynPP, Kumar-SinghS, Van BroeckhovenC (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature442, 920–924.
4.
BorroniB, PadovaniA (2013) Dementia: A new algorithm for molecular diagnostics in FTLD. Nat Rev Neurol9, 241–242.
5.
van SwietenJC, HeutinkP (2008) Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol7, 965–974.
BrouwersN, NuytemansK, van der ZeeJ, GijselinckI, EngelborghsS, TheunsJ, Kumar-SinghS, PickutBA, PalsP, DermautB, BogaertsV, De PooterT, SerneelsS, Van den BroeckM, CuijtI, MattheijssensM, PeetersK, SciotR, MartinJJ, CrasP, SantensP, VandenbergheR, De DeynPP, CrutsM, Van BroeckhovenC, SleegersK (2007) Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol64, 1436–1446.
8.
RademakersR, BakerM, GassJ, AdamsonJ, HueyED, MomeniP, SpinaS, CoppolaG, KarydasAM, StewartH, JohnsonN, HsiungGY, KelleyB, KuntzK, SteinbartE, WoodEM, YuCE, JosephsK, SorensonE, WomackKB, WeintraubS, Pickering-BrownSM, SchofieldPR, BrooksWS, Van DeerlinVM, SnowdenJ, ClarkCM, KerteszA, BoylanK, GhettiB, NearyD, SchellenbergGD, BeachTG, MesulamM, MannD, GrafmanJ, MackenzieIR, FeldmanH, BirdT, PetersenR, KnopmanD, BoeveB, GeschwindDH, MillerB, WszolekZ, LippaC, BigioEH, DicksonD, Graff-RadfordN, HuttonM (2007) Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C–>T (Arg493X) mutation: An international initiative. Lancet Neurol6, 857–868.
9.
RohrerJD, RidgwayGR, ModatM, OurselinS, MeadS, FoxNC, RossorMN, WarrenJD (2010) Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage53, 1070–1076.
FinchN, BakerM, CrookR, SwansonK, KuntzK, SurteesR, BisceglioG, Rovelet-LecruxA, BoeveB, PetersenRC, DicksonDW, YounkinSG, DeramecourtV, CrookJ, Graff-RadfordNR, RademakersR (2009) Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain132, 583–591.
13.
CarecchioM, FenoglioC, De RizM, GuidiI, ComiC, CortiniF, VenturelliE, RestelliI, CantoniC, BresolinN, MonacoF, ScarpiniE, GalimbertiD (2009) Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer’s disease. J Neurol Sci287, 291–293.
14.
PlonSE, EcclesDM, EastonD, FoulkesWD, GenuardiM, GreenblattMS, HogervorstFB, HoogerbruggeN, SpurdleAB, TavtigianSV, IARC Unclassified Genetic Variants Working Group (2008) Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat29, 1282–1291.
